PedAM
Pediatric Disease Annotations & Medicines
| burning mouth syndrome | ||||
| Disease ID | 373 |
|---|---|
| Disease | burning mouth syndrome |
| Definition | A group of painful oral symptoms associated with a burning or similar sensation. There is usually a significant organic component with a degree of functional overlay; it is not limited to the psychophysiologic group of disorders. |
| Synonym | bms - burning mouth syndrome burning mouth syndrome (disorder) burning mouth syndrome [disease/finding] burning mouth syndromes dysesthesia oral mouth syndrome, burning mouth syndromes, burning oral dysaesthesia oral dysesthesia orodynia stomatopyrosis syndrome, burning mouth syndromes, burning mouth |
| DOID | |
| UMLS | C0006430 |
| MeSH | |
| SNOMED-CT | |
| Comorbidity | UMLS | Disease | Sentences' Count(Total Sentences:6) C0003467 | anxiety | 2 C0011570 | depression | 1 C0037317 | sleep disturbance | 1 C0039494 | temporomandibular disorders | 1 C0752347 | lewy body disease | 1 C0039494 | temporomandibular disorder | 1 |
| Curated Gene | (Waiting for update.) |
| Inferring Gene | Entrez_id | Symbol | Resource(Total Genes:2) |
| Text Mined Gene | Entrez_id | Symbol | Score | Resource(Total Genes:50) 3861 | KRT14 | DISEASES 1511 | CTSG | DISEASES 973 | CD79A | DISEASES 3558 | IL2 | DISEASES 1432 | MAPK14 | DISEASES 2023 | ENO1 | DISEASES 6737 | TRIM21 | DISEASES 1830 | DSG3 | DISEASES 1828 | DSG1 | DISEASES 80326 | WNT10A | DISEASES 1593 | CYP27A1 | DISEASES 3569 | IL6 | DISEASES 7097 | TLR2 | DISEASES 6741 | SSB | DISEASES 6532 | SLC6A4 | DISEASES 8989 | TRPA1 | DISEASES 5024 | P2RX3 | DISEASES 3553 | IL1B | DISEASES 3858 | KRT10 | DISEASES 3868 | KRT16 | DISEASES 4589 | MUC7 | DISEASES 2915 | GRM5 | DISEASES 9451 | EIF2AK3 | DISEASES 767 | CA8 | DISEASES 7173 | TPO | DISEASES 6863 | TAC1 | DISEASES 254887 | ZDHHC23 | DISEASES 6050 | RNH1 | DISEASES 100506658 | OCLN | DISEASES 54879 | ST7L | DISEASES 722 | C4BPA | DISEASES 7391 | USF1 | DISEASES 4582 | MUC1 | DISEASES 4803 | NGF | DISEASES 8518 | IKBKAP | DISEASES 3339 | HSPG2 | DISEASES 4958 | OMD | DISEASES 765 | CA6 | DISEASES 8544 | PIR | DISEASES 594857 | NPS | DISEASES 7442 | TRPV1 | DISEASES 643418 | LIPN | DISEASES 7018 | TF | DISEASES 6335 | SCN9A | DISEASES 9048 | ARTN | DISEASES 7124 | TNF | DISEASES 2668 | GDNF | DISEASES 627 | BDNF | DISEASES 8972 | MGAM | DISEASES 26085 | KLK13 | DISEASES |
| Locus | (Waiting for update.) |
| Disease ID | 373 |
|---|---|
| Disease | burning mouth syndrome |
| Integrated Phenotype | (Waiting for update.) |
| Text Mined Phenotype | HPO | Name | Sentences' Count(Total Phenotypes:7) HP:0000739 | Anxiety | 2 HP:0000217 | Dry mouth syndrome | 2 HP:0012531 | Pain | 2 HP:0000708 | Behavioral problems | 1 HP:0002360 | Sleep disturbance | 1 HP:0000716 | Depression | 1 HP:0000221 | Scrotal tongue | 1 |
| Disease ID | 373 |
|---|---|
| Disease | burning mouth syndrome |
| Manually Symptom | UMLS | Name(Total Manually Symptoms:3) |
| Text Mined Symptom | UMLS | Name | Sentences' Count(Total Symptoms:1) |
Manually Genotype(Total Text Mining Genotypes:0) |
|---|
| (Waiting for update.) |
All Snps(Total Genotypes:0) | |
|---|---|
| (Waiting for update.) | |
GWASdb Annotation(Total Genotypes:0) | |
|---|---|
| (Waiting for update.) | |
GWASdb Snp Trait(Total Genotypes:0) | |
|---|---|
| (Waiting for update.) | |
Mapped by lexical matching(Total Items:0) |
|---|
| (Waiting for update.) |
Mapped by homologous gene(Total Items:1) | ||||
|---|---|---|---|---|
| HP ID | HP Name | MP ID | MP Name | Annotation |
| HP:0000716 | Depression | MP:0005402 | abnormal action potential; | |
Chemical(Total Drugs:2) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| CUI | ChemicalName | ChemicalID | CasRN | DiseaseName | DiseaseID | DirectEvidence | PubMedIDs | ||
| C0006430 | nevirapine | D019829 | 129618-40-2 | burning mouth syndrome | MESH:D002054 | marker/mechanism | 18176653 | ||
| C0006430 | zidovudine | D015215 | 30516-87-1 | burning mouth syndrome | MESH:D002054 | marker/mechanism | 18176653 | ||
FDA approved drug and dosage information(Total Drugs:6) | ||||||||
|---|---|---|---|---|---|---|---|---|
| DiseaseID | Drug_name | active_ingredients | strength | Dosage Form/Route | Marketing Status | TE code | RLD | RS |
| MESH:D002054 | retrovir | zidovudine | 100MG | CAPSULE;ORAL | Prescription | AB | Yes | Yes |
| MESH:D002054 | retrovir | zidovudine | 50MG/5ML | SYRUP;ORAL | Prescription | AA | Yes | Yes |
| MESH:D002054 | retrovir | zidovudine | 10MG/ML | INJECTABLE;INJECTION | Prescription | AP | Yes | Yes |
| MESH:D002054 | retrovir | zidovudine | 200MG | TABLET;ORAL | Discontinued | None | No | No |
| MESH:D002054 | zidovudine | zidovudine | 60MG | TABLET;ORAL | Discontinued | None | No | No |
| MESH:D002054 | zidovudine | zidovudine | 60MG | TABLET;ORAL | Discontinued | None | No | No |
FDA labeling changes(Total Drugs:6) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DiseaseID | Pediatric_Labeling_Date | Trade_Name | Generic_Name_or_Proper_Name | Indications Studied | Label Changes Summary | Product Labeling | BPCA(B) | PREA(P) | BPCA(B) and PREA(P) | Pediatric Rule (R) | Sponsor | Pediatric Exclusivity Granted Date | NNPS |
| MESH:D002054 | 6/11/2009 | retrovir | zidovudine | Treatment of HIV-1 infection in combination with other antiretroviral agents | Provided dosing recommendations for patients 4 weeks to < 6 weeks of age and weighing 4 kg to < 9 kg | Labeling | - | P | - | - | GlaxoSmithKline | - | TRUE' |
| MESH:D002054 | 6/11/2009 | retrovir | zidovudine | Treatment of HIV-1 infection in combination with other antiretroviral agents | Provided dosing recommendations for patients 4 weeks to < 6 weeks of age and weighing 4 kg to < 9 kg | Labeling | - | P | - | - | GlaxoSmithKline | - | TRUE' |
| MESH:D002054 | 6/11/2009 | retrovir | zidovudine | Treatment of HIV-1 infection in combination with other antiretroviral agents | Provided dosing recommendations for patients 4 weeks to < 6 weeks of age and weighing 4 kg to < 9 kg | Labeling | - | P | - | - | GlaxoSmithKline | - | TRUE' |
| MESH:D002054 | 6/11/2009 | retrovir | zidovudine | Treatment of HIV-1 infection in combination with other antiretroviral agents | Provided dosing recommendations for patients 4 weeks to < 6 weeks of age and weighing 4 kg to < 9 kg | Labeling | - | P | - | - | GlaxoSmithKline | - | TRUE' |
| MESH:D002054 | 09/19/2008 | retrovir syrup, capsules and tablets | zidovudine | Used in combination with 18 other antiretroviral agents for the treatment of HIV-1 infection | Dosing and administration information provided to children 6 weeks to less than 18 years of age Macrocytosis was reported in the majority of pediatric patients receiving Retrovir 180 mg/m2 every 6 hours in open-label studies New dosing regimen | Labeling | - | P | - | - | GlaxoSmithKline | - | TRUE' |
| MESH:D002054 | 6/11/2009 | retrovir | zidovudine | Treatment of HIV-1 infection in combination with other antiretroviral agents | Provided dosing recommendations for patients 4 weeks to < 6 weeks of age and weighing 4 kg to < 9 kg | Labeling | - | P | - | - | GlaxoSmithKline | - | TRUE' |